Sutimlimab
Based on 1 Customer Validation
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome.
For research use only. We do not sell to patients.
- Purity : 98.81%
- CAS No.: 2049079-64-1
- Molecular Weight:144.8 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
C1s
In Vitro
Sutimlimab (30 μg/mL) can significantly protect CD46KO cells from complement-mediated cell death, with a relative 1-hour luminescence recovery rate of 73%[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized C1s/Complement component C1s Protein, Human can bind Sutimlimab. The EC50 for this effect is 16.31 ng/mL. -
Flow Cytometry analysis of A549 cells labelling C1s (red) with Sutimlimab (anti-C1s) (HY-P99050). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2049079-64-1
-
Appearance Liquid
-
Molecular Weight 144.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Sutimlimab]
-
Synonyms
BIVV009; IPN-009; TNT009
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Alexander Röth, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334. [Content Brief]
[2]. Cole MA, et al. Complement Biosensors Identify a Classical Pathway Stimulus in Complement-Mediated Hemolytic Uremic Syndrome. bioRxiv [Preprint]. 2024 Jun 2:2024.05.29.596475. [Content Brief]
[3]. Berentsen S. Sutimlimab for the Treatment of Cold Agglutinin Disease. Hemasphere. 2023 May 2;7(5):e879. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)